Enzyme immunoassay for the prostate-specific acid phosphatase (E. C. 3.1.3.2)

Prostate-specific acid phosphatase (PSAP) has been identified as a potential marker for prostate cancer. Prior research has shown that elevated PSAP levels correlate with advanced tumor stages. However, the accuracy of enzyme immunoassays (EIA) for measuring PSAP remained uncertain. No prior work had resolved whether EIA could reliably distinguish between benign and malignant prostate conditions. This gap motivated the need for a study evaluating EIA's diagnostic performance. Researchers aimed to determine if EIA could provide consistent results compared to radioimmunoassay (RIA). The study also sought to clarify PSAP's specificity in differentiating prostate cancer from other urogenital malignancies. Existing diagnostic tools lacked sufficient sensitivity for early-stage tumors. This paper contributes by analyzing PSAP levels across various clinical scenarios.

The researchers aimed to assess the diagnostic utility of enzyme immunoassay (EIA) for prostate-specific acid phosphatase (PSAP). They focused on evaluating EIA's performance in detecting PSAP across different prostate conditions. The study sought to compare EIA with radioimmunoassay (RIA) for consistency in results. A key objective was to determine if PSAP levels correlate with tumor staging in prostate cancer. The team also aimed to investigate PSAP's specificity in distinguishing prostate cancer from benign and other malignant urogenital diseases. They wanted to establish whether EIA could reliably detect elevated PSAP in advanced tumor stages. The study's design included analyzing serum samples from patients with various prostate-related conditions. The goal was to provide evidence for EIA's potential in clinical tumor monitoring.

The study analyzed 227 serum samples using enzyme immunoassay (EIA) for prostate-specific acid phosphatase (PSAP). Samples were collected from patients with prostate cancer, benign prostatic hyperplasia, prostatitis, and other urogenital malignancies. The researchers categorized patients based on tumor staging (T1–T4) and disease type. PSAP levels were measured using EIA, with a threshold of 1 ng/ml as the cutoff for elevated values. A subset of samples was also tested using radioimmunoassay (RIA) for comparative analysis. The team compared EIA results across different tumor stages and benign conditions. They calculated the proportion of patients with PSAP levels above 1 ng/ml in each group. The study's design allowed for evaluating EIA's diagnostic accuracy and specificity in clinical settings.

The enzyme immunoassay (EIA) detected elevated prostate-specific acid phosphatase (PSAP) levels in 19 of 19 T4 stage prostate cancer patients. PSAP levels exceeded 1 ng/ml in 16 of 16 T3 stage patients and 11 or 12 of 12 T2 stage patients. In T1 stage patients, only 5 of 13 had PSAP levels above 1 ng/ml. The EIA showed high specificity, with 131 of 137 benign and non-prostate malignancies having PSAP under 1 ng/ml. Prostatic adenomas and prostatitis samples had low PSAP levels in most cases. Bladder and renal carcinomas also showed minimal PSAP elevation. The correlation between EIA and radioimmunoassay (RIA) results was strong. These findings suggest EIA's potential for tumor staging and monitoring.

The study demonstrates that enzyme immunoassay (EIA) for prostate-specific acid phosphatase (PSAP) correlates with tumor staging in prostate cancer. Elevated PSAP levels were most frequently observed in advanced tumor stages (T3 and T4). The authors propose that EIA could serve as a diagnostic tool for monitoring prostate cancer progression. The high specificity of EIA in distinguishing benign from malignant conditions supports its clinical relevance. The strong correlation with radioimmunoassay (RIA) suggests EIA's reliability in measuring PSAP. The authors suggest that PSAP levels may reflect tumor burden in later stages. They emphasize that EIA's performance in detecting elevated PSAP in T3 and T4 stages is notable. The findings indicate that EIA could complement existing diagnostic methods in clinical practice.